Niox Group Plc engages in the design, development, and commercialization of medical devices for the diagnosis and management of asthma. The company is headquartered in Oxford, Oxfordshire and currently employs 84 full-time employees. The company went IPO on 2014-03-13. The firm is engaged in the design, development, and commercialization of medical devices for the measurement of fractional exhaled nitric oxide (FeNO), a precise biomarker for asthma. The firm's NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm offers products and services in around 50 countries.